Johnson & Johnson announced on 6/13/2018 that the United Kingdom’s National Institute for Health and Care Excellence (NICE) has published positive guidance for Tremfya® (guselkumab), following... read more
Johnson & Johnson announced on 6/13/2018 that the United Kingdom’s National Institute for Health and Care Excellence (NICE) has published positive guidance for Tremfya® (guselkumab), following... read more
This article is part of a series on right-to-try and the FDA. Please click here to read the first article in the series.
Unfortunately we haven'... read more
Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) announced on 6/12/2018 positive top-line results from its multinational Phase II clinical study of PLX-PAD cells in the treatment of... read more
Sage Therapeutics (NASDAQ: SAGE) announced on 6/12/2018 its expedited development plan for SAGE-217 following a Breakthrough Therapy meeting with the U.S. Food and Drug Administration (FDA).... read more
